Key facts
- Illumicell AI’s last known valuation is $12.0M (Jun 2024).
- It has raised $3.2M; the latest was Equity Crowdfunding ($220K) in Dec 2025.
- Notable investors include Techstars, Creative Destruction Lab, MassChallenge, University of Toronto, Harvard Innovation Launch Lab — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Illumicell AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Illumicell AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Illumicell AI
Developer of a fertility care platform intended to bring sperm testing with accuracy to make healthcare services efficient and inclusive. The company's platform creates a diagnostic system that scans and generates structured, labeled cell data, unlocking personalized insights like lifestyle-linked fertility changes, supplement responses and early fertility decline warnings, enabling healthcare providers to streamline their clinical operations and accelerate their business growth.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2023
- Employees
- 17
- Website
- illumicell.ai/
- Ownership
- Privately Held (backing)
Illumicell AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Illumicell AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Illumicell AI in its N-PORT filings yet. We sweep new filings monthly.